enhanced repression of polycomb repressive complex2 (PCR) targets. Preclinical models of EZH2 inhibition have showed a benefit in malignant pleural mesothelioma presenting BAP1 loss. A phase II clinical trials evaluating the EZH2 inhibitor tazemetostat in MPM is ongoing. Additionally, a new alternative splice isoform of BAP1 has been reported to regulate DNA damage response and to influence drug sensitivity. BAP1 loss play also a role in prognostication, these patients having a much better prognosis. Another driver mutation is the CDKN2A gene located in chromosome 9p21 encoding p14 ARF and p16 INK4a which through p14 ARF interacts with MDM2 leading to MDM2 degradation and activation of p53 . In consequence loss of p14 ARF favor cell survival. On the other way loss of p16 INK4a leads to inhibition of the retinoblastoma pathway and to cell progression. CDKN2A(p16) is observed by FISH analysis in nearly 50% of malignant pleural mesothelioma to more than 80% in sarcomatoid and desmoplastic mesothelioma A large number of publications have confirmed that CDKN2A(P16) homozygous deletion by FISH testing is an accurate marker of malignancy playing a major role in the separation of benign reactive mesothelial hyperplasia versus epithelioid malignant pleural mesothelioma and more interestingly in the separation of diffuse chronic pleural fibrosis from sarcomatoid MPM. Finally the last more common driver mutation, the neurofibromin 2 gene (NF2) located at chromosome 22q12 encodes the merlin protein which regulates the hippo pathway. Next generation sequencing has showed alterations in NF2 in 20 to 50% of MPLM and In consequence the loss of NF2 results in cell proliferation and survival. The potential utility of NF2 loss was evaluated using immunohistochemistry by Sheffield et al, showing that the incidence of NF2 immunohistochemical staining was not helpful for the diagnosis of mesothelioma with a sensitivity of 4%. However, recent investigation has showed that defactinib a focal adhesion kinase (FAK) inhibitor may have a potential action on the NF2 pathway for blocking cell survival. The diverse molecular events are not exclusive and it should be expected that additional mutations may play a role in treatment sensitivity. BAP1, NF2 and p16 are the main tumor suppressor genes involve in mesothelioma important to evaluate for diagnosis, prognostication and treatment decision. Therapeutic algorithms will be presented during the session. References: Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M, Giancotti F. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.
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Targeting the Micro-RNA: A New Therapeutic Venture N. Pavlakis Medical Oncology, Royal North Shore Hospital (Sydney University), Sydney, NSW/AU Malignant pleural mesothelioma (MPM) has remained a therapeutically challenging condition since the establishment of cisplatin and pemetrexed chemotherapy (chemo) as the standard of care in suitably fit patients (1). Approaches to drug development in MPM as in cancer in general have traditionally focused on identifying specific cellular or biologic "targets" considered of importance in the cancer pathogenesis in the hope of obtaining large therapeutic impact. Unfortunately successful "targeted" therapy of advanced MPM has to date remained elusive. The arguments for these failures in MPM emphasize the complexity of the pathogenesis of MPM, characterized by alterations in multiple cellular pathways and the absence of landmark "drivers". The search for therapy by targeting fundamental pathologic processes in MPM has seen greater success. An example of this has been vascular endothelial growth factor (VEGF) signaling which has been shown to play a pivotal role in MPM pathogenesis. Targeting VEGF with the addition of the anti-VEGF monoclonal antibody bevacizumab to standard chemo in patients (pts) with advanced MPM was shown to improve survival compared with standard chemo (2). Another such approach of interest in MPM is that focusing on non-coding RNAs with their deregulation seen in MPM as in many other human cancers. MicroRNAs (miRNAs), are a subclass of non-coding RNAs with short sequences (18e24 nucleotides) that target messenger RNAs (mRNAs) through partial base pairing to sites found in their 3ʹ untranslated region (3). They regulate gene expression post-transcriptionally by blocking the translation of target mRNAs. Over 1000 human miRNAs have been identified with roles in the control of gene and protein expression (4). In MPM several miRNA expression profiles have been identified in tissue and in blood (serum or plasma) as potential biomarkers of MPM, with possible a role in diagnosis and prognosis (5, 6) . Several dysregulated miRNAs have also been associated with the pathogenesis of MPM affecting many of the hallmarks of cancer, by being downregulated and thus losing their tumour suppressor functions (5). Thus, developing a therapeutic approach to MPM by targeting miRNAs has focused on restoring the levels of deficient miRNA. Therapeutic miRNA replacement to date has mainly focused on the use of synthetic miRNA mimics to restore lost tumor suppressor expression (7). The miRNA-15/16 family specifically has been shown to be downregulated and to have a tumour suppressor function in MPM , targeting the mRNAs of BCL2, CDK1, ETS1, and JUN, which are all involved in cancer progression (7, 8) . Based on this finding Reid et al focused on developing a therapeutic strategy targeting miRNA-16 (miR-16). Firstly they showed in vitro that restoring miR-15 and -16 expression inhibited MPM cell growth and that systemic delivery of a miR-16 mimic inhibits tumour growth in vivo (8). Furthermore, in vitro, miR-16 restoration increased the sensitivity of cells to gemcitabine and pemetrexed chemo (8).Reid et al used an alternative to the liposomal or nanoparticle based methods frequently used to deliver miR-NAs, by employing EnGeneIC Dream Vectors (EDV TM ) nanocells (EDVs) (7, 8, 9) . This is a bacterially derived delivery system developed by EnGeneIC Ltd (Sydney, Australia) and comprises nonviable minicells 400 +/-20 nm in diameter, which were loaded with a miR-16 mimic, and coated with bispecific antibody to EGFR (panitumumab), as EGFR is known to be expressed in a high proportion of mesothelioma patients (7, 8, 9) . These pre-clinical experiments were followed by a first in man open label, phase 1, dose-escalation escalation study in patients with refractory advanced MPM aimed to assess the safety, optimal dosing, and activity of TargomiRs (the aforementioned EDV minicells loaded with miR-16-based miRNA targeted to EGFR (10)). Patients were given TargomiRs via 20 min intravenous IV) infusion either once or twice a week (3 days apart) in a traditional 3 + 3 dose-escalation design in five dose cohorts. Several dose-escalation steps were planned either once or twice weekly, but after analysis of data from the first eight pts, all subsequent patients started protocol treatment at 1 x 10⁹ TargomiRs. The primary endpoints were to establish the maximum tolerated dose (MTD), defined by dose-limiting toxicity, to define the optimal administration schedule and to explore anti-tumour activity (10). Twenty six enrolled pts received at least one TargomiR dose. Overall, 5 DLTs were noted: infusion-related inflammatory symptoms and coronary ischaemia, respectively, in 2 pts given 5 x 10⁹ TargomiRs twice weekly; anaphylaxis and cardiomyopathy, respectively, in two pts given 5 x 10⁹ TargomiRs once weekly but who received reduced dexamethasone prophylaxis; and non-cardiac pain in one pt who received 5 x 10⁹ TargomiRs once weekly. MTD was 5 x 10⁹ TargomiRs once weekly. TargomiR infusions were accompanied by transient lymphopenia (25 /26 pts), temporal hypophosphataemia (17/26 [65%] pts), increased aspartate aminotransferase or alanine aminotranferase (6/26 [23%] pts), and increased alkaline phosphatase blood concentrations (2/26 [8%]). Cardiac events occurred in 5 pts: 3 with ECG changes, one pt had ischaemia, one pt had Takotsubo cardiomyopathy. 22 pts were evaluable for response: one (5%) partial response, 15 (68%) stable disease, six (27%) progressive disease. The duration of response in the responding pt was 32 weeks. Median overall survival was 200 days (95% CI 94e358)(10). This phase I study demonstrated acceptable safety and signs of activity of TargomiRs acting as proof of concept supporting further development in pts with refractory MPM. The optimal next step is not clear. Possibilities include a formal Phase II study evaluating TargomiRs in the weekly or alternative schedules or combination studies with chemo or immune checkpoint inhibitors. Another novel combination option has been suggested by the recently identified link between the fibroblast growth factor axis and the miR-16 family (11) Real world evidence (RWE) research becomes more important than before since data about real-world effectiveness and safety might impact the reimbursement and utilization of new but pretty expensive drugs or medical devices in precision medicine and immune-oncology era. The data are requested more by regulators, public and private payers as well as patients and physicians, all of whom seek to better understand the impact or usefulness of the drugs or medical devices either already approved for the indication or under approval process for the expansion of the indication in a real-world setting. Ministry of Food and Drug Safety (MFDS) formerly known as Korean Food and Drug Administration requires post-approval research or post-market surveillance to determine real world safety due to concerns about unexpected safety and complications in a larger population while it does not require the data about real world efficacy and cost-effectiveness after approval. However, National Health Insurance Service (NHIS) and Health Insurance Review and Assessment Service (HIRA), only one governmental payer in Korea, may need real world clinical effectiveness and cost-effectiveness of both drugs, especially moleculartargeted agents and immune checkpoint inhibitors, and medical devices, such as next generation-sequencing, after the coverage. Actually, the decision whether to approve or reimburse a drug or medical device is usually made based on a prior large clinical trial(s) which have already given both clinical efficacy and safety profile but not costeffectiveness and/or budget impact on the healthcare system. Costeffectiveness can often be addressed in a longer time or from assumptions based on the results of prior clinical trials. Nevertheless, the Korean reimbursement system has to decide whether to cover drugs or medical devices for patient's request as well as company's one without solid cost-effectiveness data. In addition, most of the trials were conducted outside Korea or included a few Korean patients, requiring more information from a larger Korean population who might different age groups, different genders and different molecular backgrounds in the real world from the population included in the clinical trials. Therefore, the data about real-world Korean patient experience have the potential to improve the quality and delivery of medical care in Korea but also reduce overall costs by reducing or fixing gaps between clinical trials and real clinical practice. Especially, as some immune checkpoint inhibitors or next generation sequencing has been reimbursed since 2017, the NHIS and HIRA recognizes the importance of RWE and need of RWE research or comparative effectiveness research. However, there are some barriers to be overcome for the research. First of all, all of clinical data which are needed for the research should be collected well. All claims from providers in Korea are submitted electronically to the NHIS using a computer with software that meets electronic filling requirements, which are later reviewed by the HIRA. Fortunately, since there is only one insurance system run by government in Korea, therefore the claims seem good as clinical data. However, the requirement is rather optimized to or fitted more in with billing service while personally identifiable information on beneficiaries is obtained as little as possible, which, makes electronic data captured less useful for real world evidence research. Some clinical data, such as demographic or survival related data, are also collected by another governmental organization, Statics Korea, but electronic data interchange between the organizations is rather difficult due to enforced domestic laws, personal information protection act. Merging clinical data already electronically obtained has one of the barriers to be overcome. Sometimes more data should be captured separately or in addition to those from the current electronic health claims or governmental organization. Therefore, we have to overcome barriers related to collection of clinical data. Fortunately, all providers in Korea use electronic medical records. Secondly, resources for the research including research personnel, funding process and supporting infrastructures, are also a big issue. Most of clinical trials for developing drugs or medical devices are initiated or sponsored by companies which are very familiar to clinical trials from designing through conducting to analyzing and reporting steps. However, real world evidence research is usually initiated, sponsored or supported by the organizations running health care reimbursement system which are not familiar as much as companies. The research itself are not familiar to most investigators or contract research organizations as well. The research budget is not also easily estimated and therefore funding for each research becomes another problem. In addition, the funding source is also debatable. Thirdly, generation of a high level of trust from stakeholders is another issue. Due to the nature of real world evidence research such as data collection and research design, studies in general could not yield definitive conclusions because of the many confounding factors. Therefore, a framework should be in place to facilitate the development of trust and to reduce the uncertainty. Establishment of independent organizations, such as Patient-Centered Outcomes Research Institute (PCORI), can be considered. A kind of credit or incentive can considered as well for stakeholders The participation of all stakeholders mght be important for a high level of traust. The governmental organizations in Korea, NHIS and HIRA as well as Ministry of Health and Welfare, have already started consultation to and discussion with healthcare sector stakeholders including academic researchers and product developers as well as patient advocacy groups to develop draft guidance of the use of RWE and then to embed the evidence in the reimbursement and regulations. Although there still remain many challenges or barriers to be overcome at many different levels, it is kept in our mind that quality and transparency at each stage of RWE generation will be critical for all stakeholders. Keywords: Clinical Data, Barriers, Real World Evidence MS26.02 Translation of Clinical Data to Real World -North America C. Ho Medical Oncology, BC Cancer, Vancouver, BC/CA Clinical trials assist oncologic treatments in moving forward; enabling the creation of new benchmarks for quality care for lung cancer patients. Beyond the demonstration of efficacy however, is the implementation of change in the real world. For some nations, the health care structure is responsive and for others there are multiple steps required
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